We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00551967
Recruitment Status : Active, not recruiting
First Posted : November 1, 2007
Last Update Posted : May 3, 2017
Zimmer Biomet
Information provided by (Responsible Party):
Henrik Malchau, Massachusetts General Hospital

October 30, 2007
November 1, 2007
May 3, 2017
October 2007
December 2022   (Final data collection date for primary outcome measure)
Short-term femoral head penetration,long-term steady state wear of polyethylene. Stability of acetabular & femoral components. Clinical questionnaires to assess preop,clinical outcomes,& patient satisfaction. [ Time Frame: 5 years ]
Same as current
Complete list of historical versions of study NCT00551967 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary THA Using RSA
Evaluation of the Wear of Vitamin E Treated Polyethylene Components in Primary Total Hip Arthroplasty Using Radiostereometric Analysis (RSA)
The specific aim of this proposed study is to conduct a prospective RSA clinical study at Massachusetts General Hospital involving 50 patients receiving primary total hip replacements. All patients will receive the vitamin E treated polyethylene acetabular inserts. Short-term femoral head penetration and long-term steady state wear of the polyethylene will be measured using both RSA and Martell analysis techniques. Stability of the acetabular and femoral components will be measured in all patients using RSA analysis. The stability of the cemented femoral stems will be compared to the stability of the cementless femoral components as well as to historic data in the literature. In addition, all patients will complete a self-administered questionnaire to assess the clinical outcome of the surgery and patient satisfaction.
Not Provided
Not Provided
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Osteoarthritis of Hip
  • Traumatic Arthritis of Hip
Procedure: Hip replacement
Surgical implantation of hip replacement components for the treatment of osteoarthritis
Active Comparator: E1 polyethylene
All patients received an E1 polyethylene liner which is the material being monitored in this study.
Intervention: Procedure: Hip replacement
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
December 2022
December 2022   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female
  • 20 to 75 years of age
  • Subjects requiring primary total hip replacement
  • Subjects with diagnosis of osteoarthritis, avascular necrosis, or traumatic arthritis
  • Subjects who demonstrate the ability to return to MGH for follow-up for the next five years.

Exclusion Criteria:

  • Subjects with limited life span
  • Subjects with difficulty in comprehending study protocol for any reason.
  • Subjects with inflammatory disease, previous infection or those requiring revision hip surgery.
  • Subjects whose bony structures are so small that a femoral head less than 32mm in diameter must be used.
  • Subjects whose bony structure deviates substantially from the general norm sufficiently to require non-standard techniques and non-standard implants. Specific examples of these are total dislocation of the hip, severe coxa vera deformity, severe forms of multiple epiphyseal dysplasia
  • Subjects with complex disease entities which significantly increase the risks of the surgery such as any major platelet abnormality, hematological disorder, positive for HIV or any other major medical complication which substantially reduces longevity.
  • Female subjects that are pregnant or who may suspect they are pregnant or who plan to become pregnant while participating in this study.
Sexes Eligible for Study: All
20 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Henrik Malchau, Massachusetts General Hospital
Massachusetts General Hospital
Zimmer Biomet
Principal Investigator: Henrik Malchau, MD, PhD Massachusetts General Hospital
Massachusetts General Hospital
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP